About EmVenio Research
EmVenio Research is a Healthcare company based in Durham (United States) founded in 2020, and was acquired by PCM Trials in February 2024. Clinical trials support, patient engagement, and research services are provided. EmVenio Research has raised $13.67 million across 2 funding rounds from investors including PCM Trials. Its chief executive, as recorded, is Keith Henthorne. Its website emvenio.com draws about 12 thousand monthly visits. EmVenio Research offers products and services including Global Site Network, Mobile and Virtual Visits, Patient Engagement, and Community Engagement. Its focus areas include Services for Healthcare Providers, Patient Engagement, Home Healthcare and House Call. Its competitors include Landmark Health, Jet Health and Bright Health Group; 2 of its 3 listed competitors have raised funding.
Company details
EmVenio Research was founded in 2020 and is headquartered in Durham, United States. Operations focus on the healthcare sector, where clinical trials support is offered alongside patient engagement initiatives and general research services. These activities are conducted to facilitate medical studies and participant involvement. Leadership is provided by CEO Keith Henthorne, with services targeted at research organizations and healthcare providers in the region.
- Headquarters Durham, United States
- Stage Acquired
- SectorsHealthcare
- Email••••••••
- Website emvenio.com
- Social LinkedIn X Facebook Instagram
- Acquired by PCM Trials (Feb 2024)
- Total Equity Funding$13.67M (USD)
in 2 rounds
- Latest Funding Round$9.17M (USD), Series A
Dec 2022
- Investors
- Acquired byPCM Trials
(Feb 2024)
Products & Services of EmVenio Research
EmVenio Research offers a comprehensive portfolio of products and services, including Global Site Network, Mobile and Virtual Visits, Patient Engagement, and Community Engagement.
Network of sites for conducting clinical trials in communities.
Flexible visits that bring clinical trials directly to participants.
Strategies for engaging and retaining diverse patient groups.
Community-based model for recruiting underrepresented populations.
Funding Insights of EmVenio Research
EmVenio Research has successfully raised a total of $13.67M across 2 strategic funding rounds. The most recent funding activity was a Series A round of $9.17 million completed in December 2022. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $13.67M
- Total Rounds 2
- Last Round Series A — $9.17M
- First Round $4.5M
(Aug 2022)
All 2 funding rounds of EmVenio Research with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Dec 2022 | $9.17M | Series A | – | – | – |
| Aug 2022 | $4.5M | Series A | – | – | – |
1 investors in total: 1 institutional.
Investors in EmVenio Research
EmVenio Research has secured backing from 1 investor. Prominent investors backing the company include PCM Trials.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Offers clinical trial networks and mobile services for sponsors worldwide. | 2008 | pcmtrials.com | Denver, United States |
Investor details for EmVenio Research
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
People of EmVenio Research
25 people are tracked at EmVenio Research (12 in leadership, 13 in team).
| Name | Role | Group |
|---|---|---|
Keith Henthorne | CEO | Leadership |
Monty Waugh | VP of Finance and Interim HR | Leadership |
Bindu J. | Director, Medical Affairs | Leadership |
Katy Keating | Marketing Director | Leadership |
Phillip Stanford | Senior Director, Applications & PMO | Leadership |
Mark McKenzie, M.D. | Chief Medical Officer | Leadership |
Daniel Castillo, MD, MBA | Co-founder, Growth and Medical Executive | Leadership |
David Shackelton | Chief Financial Officer | Leadership |
Brooke Coonradt | Director, Clinical Trial Optimization | Leadership |
Scott Carson | Senior Director Business Development | Leadership |
Lou Cappoli | Senior Director Of Clinical Trial Delivery Strategy | Leadership |
Kimberly Fehring | Director Of Operations | Leadership |
Geraldi Prajnamitra | Associate Application Product Manager | Team |
sano samuel | Information Technology Support Engineer | Team |
Kentoiya M. DeShazer DeShazer, MSN, MHA, CHC, CLC, INS, RN | Clinical Research Nurse | Team |
Julie C. | Project Owner/administrator Customer Satisfaction Surveys | Team |
Tasneem Falah | Clinical Research Coordinator | Team |
Antwonette Burton Msn | Nurse Practitioner/ Sub Investigator | Team |
Suzanne Swan M.D. | Principal Investigator | Team |
Nicole L. | Global Project Manager | Team |
5 more people are available in the full profile.
Complete people profiles for EmVenio Research
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
Timeline of EmVenio Research
4 dated milestones of EmVenio Research across 4 years, from founding to its latest funding, stage changes and deals.
- Founded EmVenio Research is founded.
- Funding First funding round of $4.5M.
- Funding Latest funding round, Series A, of $9.2M.
- Exit Acquired by PCM Trials.
Competitors of EmVenio Research
EmVenio Research has 3 listed competitors in our database, 2 of them funded. They include Landmark Health, Jet Health and Bright Health Group.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| landmarkhealth.org | 2013 | Buffalo, United States | $60.9M | 765 | A medical group that delivers house calls and team-based interdisciplinary care to chronically ill population. | |
| jethealthinc.com | 2016 | Irvine, United States | $36.85M | 291 | House call medical services are provided to patients at home. | |
| brighthealthgroup.com | 2015 | Minneapolis, United States | 2,851 | Personalized care services are delivered in the healthcare sector. |
Detailed competitors of EmVenio Research
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of EmVenio Research
The website of EmVenio Research (emvenio.com) receives about 11.5K visits a month.
- Monthly visits11.5K
▼ 20% vs previous month
Top companies in Home & Rehabilitation Care
3 companies that operate in the same segment as EmVenio Research (Home & Rehabilitation Care) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Primary healthcare is delivered through telemedicine services. | 2014 | San Francisco, California, United States | USD 31.05 M | |||
A medical group that delivers house calls and team-based interdisciplinary care to chronically ill population. | 2013 | Buffalo, New York, United States | USD 60.9 M | 765 | ||
Substance abuse therapy centers are operated nationwide for recovery support. | 2014 | Burlington, Vermont, United States | USD 60 M |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Emvenio Research
Complete news archive for EmVenio Research
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about EmVenio Research
EmVenio Research was founded in 2020 and raised its 1st funding round 2 years after it was founded.
EmVenio Research is headquartered in Durham, United States. It is registered at Durham, North Carolina, United States.
Keith Henthorne is the CEO of EmVenio Research, as recorded in our data.
EmVenio Research is a funded company, having raised a total of $13.67M across 2 funding rounds to date. The company's 1st funding round was a Series A of $4.5M, raised on Aug 2022.
EmVenio Research was founded in 2020 and is headquartered in Durham, United States. Operations focus on the healthcare sector, where clinical trials support is offered alongside patient engagement initiatives and general research services. These activities are conducted to facilitate medical studies and participant involvement. Leadership is provided by CEO Keith Henthorne, with services targeted at research organizations and healthcare providers in the region.
EmVenio Research's top competitors include Landmark Health, Bright Health Group and Jet Health.
EmVenio Research offers Global Site Network, Mobile and Virtual Visits, Patient Engagement, and Community Engagement.
EmVenio Research has 1 investor. Key investors include PCM Trials.
Yes. EmVenio Research was acquired by PCM Trials in February 2024.